Results 161 to 170 of about 49,641 (173)

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Lancet, The, 2020
Guan-Hua Du, Jianping Zhao, Yang Jin
exaly  

Compassionate Use of Remdesivir for Patients with Severe Covid-19

New England Journal of Medicine, 2020
Norio Ohmagari, Erika Asperges, Antonella Castagna   +2 more
exaly  

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

New England Journal of Medicine, 2020
Jason D Goldman, David Shu-cheong Hui, Raffaele Bruno,MD   +2 more
exaly  

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Respiratory Medicine,the, 2021
Aneesh K Mehta, Thomas F Patterson, Carlos A Gomez   +2 more
exaly  

Remdesivir for the Treatment of Covid-19 — Final Report

New England Journal of Medicine, 2020
John H Beigel, Kay M Tomashek, Lori E Dodd   +2 more
exaly  

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Nature, 2020
Brandi N Williamson, Friederike Feldmann, Benjamin Schwarz   +2 more
exaly  

Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication

Molecular Cell, 2021
Jack Bravo, Tyler L Dangerfield, David W Taylor   +2 more
exaly  

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice

Cell Reports, 2020
Andrea J Pruijssers, Amelia S George, Sarah R Leist   +2 more
exaly  

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Proceedings of the National Academy of Sciences of the United States of America, 2020
Emmie de Wit, Friederike Feldmann, Jacqueline Cronin   +2 more
exaly  

Remdesivir against COVID-19 and Other Viral Diseases

Clinical Microbiology Reviews, 2020
Jakob J Malin, Isabelle Suárez, Priv-Doz Dr Dr Jan Rybniker   +2 more
exaly